​

Oncolytics Biotech (ONCY) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

ONCY Stock Rating

Oncolytics Biotech stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (80.00%), 2 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 2 8 Strong Sell Sell Hold Buy Strong Buy

ONCY Price Target Upside V Benchmarks

TypeNameUpside
StockOncolytics Biotech-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.22$1.22$1.22
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25421--7
Sep, 25421--7
Aug, 25411--6
Jul, 25411--6
Jun, 25411--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 13, 2025Lake StreetBuyinitialise
Sep 20, 2024Raymond JamesOutperformOutperformhold
Sep 19, 2024H.C. WainwrightBuyBuyhold
Aug 21, 2024H.C. WainwrightBuyBuyhold
Apr 04, 2024Raymond JamesOutperforminitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.41-----
Avg Forecast$-0.51$-0.43$-0.48$-0.36$0.11$0.62
High Forecast$-0.49$-0.36$-0.45$-0.36$0.11$0.62
Low Forecast$-0.52$-0.48$-0.53$-0.36$0.11$0.62
Surprise %-19.61%-----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$1.04M$1.20M$15.82M$76.35M$206.32M
High Forecast-$1.04M$1.20M$15.82M$76.35M$206.32M
Low Forecast-$1.04M$1.20M$15.82M$76.35M$206.32M
Surprise %------

Net Income Forecast

$-40M $-23M $-6M $11M $28M $45M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-27.75M-----
Avg Forecast$-34.29M$-29.24M$-32.39M$-24.24M$7.53M$41.74M
High Forecast$-33.39M$-24.20M$-30.30M$-24.24M$7.53M$41.74M
Low Forecast$-35.19M$-32.27M$-35.52M$-24.24M$7.53M$41.74M
Surprise %-19.07%-----

ONCY Forecast FAQ

Is Oncolytics Biotech stock a buy?

Oncolytics Biotech stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Oncolytics Biotech is a favorable investment for most analysts.

What is Oncolytics Biotech's price target?

Oncolytics Biotech's price target, set by 10 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.22.

How does Oncolytics Biotech stock forecast compare to its benchmarks?

Oncolytics Biotech's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Oncolytics Biotech over the past three months?

  • October 2025: 57.14% Strong Buy, 28.57% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 57.14% Strong Buy, 28.57% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 66.67% Strong Buy, 16.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Oncolytics Biotech’s EPS forecast?

Oncolytics Biotech's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.43, marking a 4.88% increase from the reported $-0.41 in 2023. Estimates for the following years are $-0.48 in 2025, $-0.36 in 2026, $0.11 in 2027, and $0.62 in 2028.

What is Oncolytics Biotech’s revenue forecast?

Oncolytics Biotech's average annual revenue forecast for its fiscal year ending in December 2024 is $1.04M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $1.2M, followed by $15.82M for 2026, $76.35M for 2027, and $206.32M for 2028.

What is Oncolytics Biotech’s net income forecast?

Oncolytics Biotech's net income forecast for the fiscal year ending in December 2024 stands at $-29.241M, representing an 5.36% increase from the reported $-27.752M in 2023. Projections indicate $-32.389M in 2025, $-24.238M in 2026, $7.53M in 2027, and $41.74M in 2028.